Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Last accessed: April 2023. vi Hack SP, Spahn J, Chen M et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab ...

Purpose: The α-FAtE score, composed of alpha-fetoprotein, alkaline phosphatase, and eosinophil levels, has been reported as a predictor of prognosis in hepatocellular carcinoma (HCC) patients treated ...

Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Cox-734, Boston, MA 02114. E-mail: [email ...

Objective Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is now approved by ...

3 Graduate School of Biomedical Sciences at Icahn School of Medicine at Mount Sinai, New York, USA Objective Advanced hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment ...

NBTXR3 is under evaluation for multiple solid tumors, with FDA Fast Track designation for head and neck squamous cell carcinoma. The first participant has been dosed on the phase 2 CONVERGE study ...